key: cord-0955148-27s8j87n
authors: Kow, Chia Siang; Ramachandram, Dinesh Sangarran; Hasan, Syed Shahzad
title: The effect of curcumin on the risk of mortality in patients with COVID‐19: A systematic review and meta‐analysis of randomized trials
date: 2022-04-28
journal: Phytother Res
DOI: 10.1002/ptr.7468
sha: 319c054a016b64ac022af117709635e1b060a50d
doc_id: 955148
cord_uid: 27s8j87n

nan

geous in reducing the progression of several inflammatory illnesses (Rattis, Ramos, & Celes, 2021) . The aforementioned effects have made curcumin one of the potential treatment options for patients with COVID-19. Since the pathophysiology of COVID-19 is known to involve life-threatening inflammatory reactions, cytokine storms, and coagulopathy, curcumin can be advantageous due to its antiinflammatory effects via the inhibition of inflammasome formation (Yin et al., 2018) . In addition, curcumin also demonstrates antiviral effects via its ability to bind to the viral primary protease (Mpro) enzyme of SARS-CoV-2, which is required for viral replication. Curcumin also prevents viral attachment and passage into the host cell with great potency (Dourado et al., 2021) . The ability of curcumin in inhibiting the virus-receptor interaction is in two ways, according to modeling studies: it inhibits both the spike protein and the ACE2 receptor (Manoharan et al., 2020) . Previously in this journal, the findings of the randomized trial reported by Hassaniazad et al. (2021) suggest that curcumin can accelerate the recovery of acute inflammatory phase in patients with COVID-19 by modulating inflammatory immune responses. Nevertheless, the mortality benefits of curcumin in patients with COVID-19 were not investigated in the aforementioned trial. Several controlled trials have been performed to validate the mortality benefits of curcumin in patients with COVID-19, and we aimed to summarize their overall efficacy in terms of mortality reduction in a systematic review and meta-analysis.

A systematic literature search with no language restriction was performed in multiple electronic databases, including PubMed, Cochrane Central Register of Controlled Trials, Google Scholar, Scopus, and preprint servers (medRxiv, Research Square, SSRN) to identify eligible studies published from inception to January 20, 2022. Two investigators (CSK and DSR) independently performed the literature screening to identify eligible studies. We adopted the following search strategy:

(curcumin OR curcuma OR diferuloylmethane OR turmeric) AND (COVID-19 OR SARS-CoV-2 OR coronavirus). In addition, the reference lists of relevant articles were also reviewed to search for additional studies. Studies eligible for inclusion were randomized controlled trials that compared the mortality outcomes between the use and nonuse of curcumin (at any dose and in any dosage form) in patients with COVID-19. We excluded single-arm trials, randomized trials that did not report mortality outcomes, and randomized trials with zero mortality events in the intervention and control arms.

The outcome of interest was all-cause mortality. Each included study was independently evaluated by two investigators (CSK and DSR), who also extracted the study characteristics. Study characteristics extracted included the first author's surname, year of publication, study design, the country where the trial was performed, mean/ median age of patients, the regimen of curcumin, the regimen of comparative agents, number of deaths in the intervention arm, and number of deaths in the control arm. Two investigators (CSK and SSH) assessed the risk of bias of the randomized trials included with Version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2), which is a standardized method for assessing potential bias in reports of randomized interventions (Sterne et al., 2019) . RoB 2 is structured into a fixed set of domains of bias, which includes "randomization", "deviations from intervention", "missing outcome data", "measurement of the outcome", and 'selection of the reported results. A proposed judgement about the risk of bias arising from each domain is generated by an algorithm, where judgment can be "Low" or "High" risk of bias or express 'Some concerns'. A random-effects model was used to estimate the pooled odds ratio for all-cause mortality with the use of curcumin relative to nonuse of curcumin, at 95% confidence intervals. We examined the heterogeneity between studies using the I 2 statistics and the χ 2 test, with 50% and significance at p < .10, respectively, indicating substantial heterogeneity. All analyses were performed using Meta XL, version 5.3 (EpiGear International, Queensland, Australia).

Our literature search yielded 764 records. After deduplication and application of the eligibility criteria, five relevant articles were shortlisted for inclusion through full-text examination. Of these, two studies were excluded since they reported no mortality events. Eventually, three randomized trials (Pawar et al., 2021; Tahmasebi et al., 2021; Valizadeh et al., 2020) were included for this meta-analysis, with a total of 260 patients with COVID-19. Details of the included trials are depicted in Table 1 .

The three included trials (Pawar et al., 2021; Tahmasebi et al., 2021; Valizadeh et al., 2020) which investigated the effect of the use of curcumin on the risk of mortality in patients with COVID-19 were randomized, double-blind, controlled trials. Two of the included trials (Tahmasebi et al., 2021; Valizadeh et al., 2020) were performed in Iran, whereas the remaining one trial (Pawar et al., 2021) was performed in India. The regimen of curcumin administered differed across the three trials: in the trials by Valizadeh et al. (2020) and Tahmasebi et al. (2021) , curcumin was administered orally as nanocurcumin at a dose of 160 mg daily for 14 and 21 days, respectively, whereas, in the trial by Pawar et al. (2021) , curcumin was administered orally at a dose of 525 mg twice daily for 14 days. The overall risk of bias as assessed by RoB 2 is presented in Table 1 Indeed, few researchers have discussed the potential for curcumin to be repurposed as an innovative therapeutic agent for the treatment of COVID-19 (Soni et al., 2020; Zahedipour et al., 2020) . As a prominent immune modulator, the mortality benefits of curcumin could stem primarily from its ability to suppress the expression of multiple pro-inflammatory cytokines in patients with COVID-19 via the inhibition of inflammasome formation. Indeed, in the trial by Valizadeh et al. (2020) curcumin as reported in our meta-analysis may be exaggerated (relative risk reduction of 77%). Future trials investigating the efficacy of curcumin in COVID-19 should recruit more participants to produce more precise mortality estimates and also preferably adjust for covariates that could confound the mortality estimates.

The authors declare no conflict of interest.

The authors confirm that the data supporting the findings of this study are available within the article. F I G U R E 1 Pooled odds ratio for all-cause mortality with the use of curcumin relative to nonuse of curcumin in patients with COVID-19

Will curcumin nanosystems be the next promising antiviral alternatives in COVID-19 treatment trials?

The effects of black pepper on the intestinal absorption and hepatic metabolism of drugs

A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients

Curcumin: A wonder drug as a preventive measure for COVID19 management

Oral curcumin with Piperine as adjuvant therapy for the treatment of COVID-19: A randomized clinical trial

Curcumin as a potential treatment for COVID-19

Curcumin, a traditional spice component, can hold the promise against COVID-19?

Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients

Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients

Curcumin suppresses IL-1β secretion and prevents inflammation through inhibition of the NLRP3 inflammasome

Potential effects of curcumin in the treatment of COVID-19 infection